Paul Tudor Jones’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.18M Buy
11,500
+7,200
+167% +$1.35M ﹤0.01% 1886
2026
Q1
$848K Sell
4,300
-32,800
-88% -$6.32M ﹤0.01% 2482
2025
Q4
$6.82M Buy
37,100
+9,750
+36% +$1.71M 0.01% 967
2025
Q3
$4.2M Buy
27,350
+6,250
+30% +$946K 0.01% 1300
2025
Q2
$2.95M Buy
21,100
+19,050
+929% +$2.67M 0.01% 1404
2025
Q1
$301K Sell
2,050
-1,350
-40% -$195K ﹤0.01% 2585
2024
Q4
$446K Buy
3,400
+750
+28% +$105K ﹤0.01% 2316
2024
Q3
$413K Buy
+2,650
New +$428K ﹤0.01% 2138
2021
Q2
Sell
-80,000
Closed -$7.96M 1599
2021
Q1
$7.96M Hold
80,000
0.16% 93
2020
Q4
$8M Buy
+80,000
New +$8.47M 0.23% 60

Other funds holding AZN

Paul Tudor Jones's AZN Position: Q2 2026 in Review

Paul Tudor Jones opened a new position in AstraZeneca (AZN) in Q2 2026: 39,644 shares worth $7.52M. The stake represents 0.01% of the portfolio and ranks #1010 among its holdings. This is a return to the name: Paul Tudor Jones previously reported a position in AZN as recently as Q3 2025.

Paul Tudor Jones first reported a position in AZN in Q2 2014 and has held it in 9 quarters since. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Paul Tudor Jones held 39,644 shares of AstraZeneca worth $7.52M as of Q2 2026.
  • AstraZeneca was a new Paul Tudor Jones position in Q2 2026.
  • AstraZeneca made up 0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #1010 holding.
  • Paul Tudor Jones first reported a position in AstraZeneca in Q2 2014 and has held it in 9 quarters since.
  • 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.